St Louis, Missouri
CNS clinical trials in St Louis, MO
69 CNS studies are recruiting participants at sites in St Louis as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
St Louis at a glance
- 69 studies are recruiting at a site in St Louis.
- By phase: Early Phase 1 (1), Phase 1 (3), Phase 1/2 (1), Phase 2 (12), Phase 3 (26), Phase 4 (1), No phase (13), Observational (12). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (38), university, hospital or other (28), government (3).
- By research area: Depression (19), Multiple Sclerosis (14), Parkinson's Disease (14), Schizophrenia (9), Epilepsy (5), Migraine (5), Bipolar Disorder (3).
- Most recent update to one of these records: November 16, 2026.
Depression studies recruiting in St Louis
Basic details from each study's public record (the 30 most recently updated of 69). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Seaport Therapeutics
- Study site
- Seaport Investigator Site
- Registry record
- NCT07065240 · updated
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Definium Therapeutics US, Inc.
- Study site
- Arch Clinical Trials, LLC
- Registry record
- NCT07592689 · updated
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- LivaNova
- Study site
- Washington University School of Medicine
- Registry record
- NCT03887715 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT06748222 · updated
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Arch Clinical Trials
- Registry record
- NCT07412756 · updated
Study of ALTO-300 in MDD
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT05922878 · updated
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT07553637 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in St Louis, MO on ClinicalTrials.gov.
Schizophrenia studies recruiting in St Louis
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
- No phase
- Ages 18 to 59
- All sexes
- Sponsor
- Washington University School of Medicine
- Study site
- Washington University
- Registry record
- NCT07853807 · updated
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3
- No phase
- Ages 18 to 59
- All sexes
- Sponsor
- Washington University School of Medicine
- Study site
- Washington University
- Registry record
- NCT07900893 · updated
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- Tekton Research, LLC - Saint Louis Psychiatry - PPDS
- Registry record
- NCT06585787 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in St Louis, MO on ClinicalTrials.gov.
Bipolar disorder studies recruiting in St Louis
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Arch Clinical Trials
- Registry record
- NCT06951711 · updated
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Arch Clinical Trials
- Registry record
- NCT07140913 · updated
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Arch Clinical Trials
- Registry record
- NCT06929273 · updated
Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in St Louis, MO on ClinicalTrials.gov.
Parkinson's disease studies recruiting in St Louis
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Registry record
- NCT06989112 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Washington University - School of Medicine ( Site 5006)
- Registry record
- NCT06952504 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Washington University Siteman Cancer Center ( Site 0031)
- Registry record
- NCT06966700 · updated
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
- Phase 2
- Ages 50 to 80
- All sexes
- Sponsor
- Yale University
- Study site
- Washington University
- Registry record
- NCT06996652 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Washington Uni School of Medicine
- Registry record
- NCT07174310 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in St Louis, MO on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in St Louis
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County · Washington University School of Medicine
- Registry record
- NCT03816345 · updated
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Phase 3
- Ages 18 to 60
- All sexes
- Sponsor
- Zenas BioPharma (USA), LLC
- Study site
- Washington University School of Medicine
- Registry record
- NCT07299019 · updated
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Phase 3
- Ages 18 to 60
- All sexes
- Sponsor
- Zenas BioPharma (USA), LLC
- Study site
- Washington University School of Medicine
- Registry record
- NCT07067463 · updated
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Celgene
- Study site
- Washington University School of Medicine
- Registry record
- NCT06782490 · updated
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Phase 3
- Ages 40 to 70
- All sexes
- Sponsor
- Novartis Pharmaceuticals
- Study site
- WA Uni School Of Med
- Registry record
- NCT06846281 · updated
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT05877963 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in St Louis, MO on ClinicalTrials.gov.
Epilepsy studies recruiting in St Louis
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study site
- Saint Louis University Medical School
- Registry record
- NCT05667142 · updated
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Neurona Therapeutics
- Study site
- Washington University at St. Louis
- Registry record
- NCT05135091 · updated
Diagnosing Epilepsy To EffeCT Change
- No phase
- Ages 18 to 75
- All sexes
- Sponsor
- Epiminder America, Inc.
- Study site
- Washington University
- Registry record
- NCT07110337 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in St Louis, MO on ClinicalTrials.gov.
Migraine studies recruiting in St Louis
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Phase 4
- Ages 18 to 70
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Washington University St Louis
- Registry record
- NCT06972056 · updated
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Sundance Clinical Research
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Sundance Clinical Research
- Registry record
- NCT07674654 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in St Louis, MO on ClinicalTrials.gov.
Ask about studies near St Louis
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections